Skip to content

Engineered extracellular vesicles targeting BACE1 reduces amyloid-beta plaque formation in a genetic mouse model of Alzheimer’s Disease

Aug 2026 · bioRxiv · 0 citations · 27 references
Biology

TL;DR

A proof-of-concept feasibility is established for EV-mediated delivery of Bace1-targeting siRNA to the brain and further development of engineered EVs as a therapeutic platform for neurodegenerative diseases is supported.

View source

Similar papers

Open access Sep 2026

Attenuation of Tau-Mediated β-Amyloid1-42 Aggregation by Native PLGA Nanoparticles and Its Relevance to Alzheimer Disease Pathology

Alzheimer’s disease (AD) is an unremitting neurodegenerative disorder characterized by the presence of extracellular β-amyloid (Aβ)-containing neuritic plaques, intracellular tau-positive neurofibrillary tangles and loss of selected neurons in the brain. Evidence suggests that aggregation of Aβ and tau via synergistic...

P. Paul, Aliza Borenstein-Katz, Klinton Shmeit et al. · 0 citations
Open access Sep 2026

Human amniotic mesenchymal stromal cell-derived extracellular vesicles reprogram microglia and prevent neurodegeneration in experimental models of Alzheimer’s disease

HAMSC-EVs exert robust anti-inflammatory and neuroprotective effects in both murine and human AD models, improving cognition, modulating glial activation, and restoring synaptic integrity, and highlight the translational potential of intranasal hAMSC-EVs as an adjuvant therapeutic strategy targeting neuro inflammation...

Andrea Papait, F. Natale, A. Silini et al. · 0 citations
Aug 2026

Fabrication of Mesoporous Manganese Nanoparticles Incorporated Aβ-Peptide Inhibits Aβ Aggregation and Alleviates Neuroinflammation Against Alzheimer's Disease.

Extracellular amyloid plaques from Aβ accumulation and intracellular neurofibrillary tangles (NFTs) from hyperphosphorylated Tau (p-Tau), both leading to neuronal dysfunction, synapse loss, and cognitive decline. Nonetheless, achieving an effective therapeutic outcome is challenging due to the limited drug bioavailabil...

Hai-Peng Lu, Chuan-Chen Hu, Ya-Ming Fu · 0 citations
Open access Aug 2026

Design and evaluation of a novel peptide-EV complex for targeted Alzheimer's disease therapy.

The rational design of H102-CP05, a 22-residue chimeric peptide that integrates the β-sheet breaker peptide H102 with the CD63-targeting anchor CP05 to enable extracellular vesicle (EV) delivery of an Aβ-inhibitory payload is reported, supporting H102-CP05 as a promising EV-displayed therapeutic candidate for AD.

V. Singh, Raja Natesan Sella · 0 citations
Sep 2026

Targeting neuronal injury with intranasal Arc-engineered exosomes rescues cognitive deficits in Alzheimer's disease via the mTOR-autophagy pathway.

E engineered exosomes are highlighted as efficient nanoplatforms for precision therapy in neurodegenerative diseases by reducing β-amyloid deposition, suppressing neuroinflammation, and repairing neuronal damage in AD.

Chun-Bin Sun, S. Sha, Jian Kang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.